Pembrolizumab and weekly paclitaxel for platinum-resistant ovarian cancer скачать в хорошем качестве

Pembrolizumab and weekly paclitaxel for platinum-resistant ovarian cancer

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Robert Wenham and Angeles Alvarez Secord to discuss Pembrolizumab and weekly paclitaxel for platinum-resistant ovarian cancer (https://www.international-journal-of-...) .   Dr. Robert Wenham is a gynecologic oncologist and Chair of the Gynecologic Oncology Program at Moffitt Cancer Center.  Dr. Wenham has a strong interest in research and is a principal investigator for numerous clinical trials to improve cancer care for women.  His research activities include the use of novel drugs for the treatment of gynecologic cancers.  He has received the Molly Cade Ovarian Cancer Research Award from the Gynecologic Cancer Foundation.  Dr. Wenham enjoys the challenge of helping women with complex issues and the opportunity to offer them cutting-edge therapies, from the latest chemotherapy approaches to biologically targeted therapies, minimally invasive surgery, and clinical trials.  He is also an expert in pelvic exenteration surgery, a very complex operation that offers hope of a possible cure for certain patients with gynecologic cancer.  Clinically, he prefers a more collaborative approach where the patient plays an active role in decisions as he guides them through the pros and cons of their options.     Angeles Alvarez Secord, MD, MHSc, is a professor in the Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Duke University Heath System. She received her undergraduate degree with honors from Carroll College in Helena, Montana and graduated AOA with honors from the University of Washington School of Medicine in Seattle, Washington. Dr. Secord completed her residency in obstetrics and gynecology and her fellowship in gynecologic oncology at the Duke University Medical Center in Durham, North Carolina. Upon completing her fellowship in 2001, she joined the Division of Gynecologic Oncology at Duke. She is currently Director of Gynecologic Oncology Clinical Trials, Associate Director of Clinical Research, Gynecology Oncology, and one of the Principal Investigators for NRG Oncology at the Duke Cancer Institute. Dr. Secord serves on the GOG Foundation Board of Directors. She is passionate about mentoring the next generation of investigators and serves as the GOG Foundation Education and Mentoring Chair and the NRG Oncology Investigator and Career Development Committee Vice-Chair. Dr. Secord is a fellow of the American College of Obstetricians and Gynecologists and an active member of American Society of Clinical Oncology, American Gynecological & Obstetrical Society, Society of Gynecology & Oncology, and International Gynecologic Cancer Society as well as other professional organizations.